

## Drugs and Pharmaceuticals Industry Highlights

### Contents

Chapter	Page	Chapter	Page
<b>Feature</b>	<b>1</b>	– Government plans cap on trade margins	
– Pharma firms look forward to innovative research		– DCGI may have to inform chemical ministry of new marketing approval	
<b>News &amp; Views</b>		– Proposal for new pharma ministry	
<b>Indian</b>		– Drug manufacturers may fall under narcotics act	
<b>Industry News</b>	<b>5</b>	– Madras high court stays govt. order to withdraw 294 FDC drugs	
– Indian CROs attract private equity players		<b>Global News</b>	<b>21</b>
– OTC drugs may find place in post offices		– Bristol Myers to cut 4,800 workforce	
– Pharma firms go slow on acquisition mode		– US government takes initiative to improve import safety	
– Glenmark plans to foray into Indonesia		– Middle East to see single digit growth by 2011	
– India, Canada to collaborate on pharma opportunities		<b>Healthcare News</b>	<b>24</b>
– Strides, Aspen sign four deals		– Indians have lack of AIDS knowledge, says study	
– Government to allow Dr. Reddy's & Emmellen Biotech to set up opium business		– Aggressive TB control can yield big economic gains: World bank study	
– Ethypharm India to foray into US, Europe		– Gates foundation gives \$100 million for polio eradication	
– Pharma market making inroads in rural areas		<b>Product News</b>	<b>26</b>
– Eli Lilly increases presence in India		– Ranbaxy recalls 73m gabapentin tablets in US	
– Ranbaxy raises stake in Zenotech Labs to 34.3%		– HIV drug resistance seen in China: Expert	
<b>Regulatory News</b>	<b>10</b>	– Novartis not to market prexige in India	
– Ceiling prices fixation		– Wockhardt gets USFDA nod for ranitidine	
– IMPF supports drug price control demand			
– DCGI to use special powers to keep 294 FDC drugs out of market			
– R&D sops for pharma cos may extend to 2015			

- 150 mg
- Natco pharma launches breast cancer drug
- US FDA adds boxed warning for heart-related risks to anti-diabetes drug
- Novel drug for parkinson's disease in clinical development
- Roche presents positive phase III results for novel rheumatoid arthritis candidate
- Ranbaxy gets USFDA nod for two paediatric ARV drugs

### **R&D News** 29

- Strategic move by pharma firms to demerge R&D units
- Ranbaxy to demerge drug discovery unit
- NPIL, Merck enter research deal for cancer drugs
- Jubilant enters drug discovery pact with US firm
- Dr Reddy's plans to increase R&D spend
- Amylin enters research collaboration with Xenome
- Pfizer and Adolor enter into exclusive worldwide collaboration
- Nicholas unlikely to go ahead with chikungunya research venture

### **Biotechnology** 33

- WHO unsatisfied with GMP implementation by few vaccine manufacturers
- Pharma firms eye big insulin therapy market
- Panacea biotech plans to acquire firms in US, Europe
- GlaxoSmithKline and Oncomed pharmaceuticals form strategic alliance

- Novartis strengthens biologics capabilities in Morphosys collaboration
- Sanofi-Pasteur gives positive result in phase II trial

### **Natural Products** 36

- Kundru may lower blood sugar
- Need to diversify herbal drug industry

### **Patents** 38

- Recent Indian patents in the field of drugs and pharmaceuticals
- Indian pharma prefers non-litigation in US
- Sun settles patent row with Novartis
- Venus remedies files patent for meningitis formula
- Glaxo drops patent claims on two anti-AIDS drugs
- Zydus bets big on off-patent generics
- Seven gets two patents from EPO
- Abbott files law suit in US court against Zydus Cadila
- GAO asks US to classify US trade policy on access to medicines
- GSK wins preliminary injunction blocking new US patent rules
- Astrazeneca files patent infringement actions in response to Crestor™ Andas

### **Parliament News**

#### **Lok Sabha** 62

- Fixed dose combinations
- Clinical trials by multinational companies